BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36056858)

  • 41. [PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA].
    Elitzur S; Izraeli S
    Harefuah; 2023 Jan; 162(1):57-63. PubMed ID: 36714944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
    Fabrizio VA; Curran KJ
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101305. PubMed ID: 34625231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.
    Ivanov AV; Alecsa MS; Popescu R; Starcea MI; Mocanu AM; Rusu C; Miron IC
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia.
    Laetsch TW; Yanik GA; Boyer MW; Rheingold SR
    Blood Rev; 2021 Nov; 50():100848. PubMed ID: 33994222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia.
    Tardif M; Souza A; Krajinovic M; Bittencourt H; Tran TH
    Expert Opin Pharmacother; 2021 Oct; 22(14):1871-1887. PubMed ID: 34011251
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential impact of CAR T-cell treatment delays on society.
    Thornton Snider J; Brauer M; Kee R; Batt K; Karaca-Mandic P; Zhang J; Goldman DP
    Am J Manag Care; 2019 Aug; 25(8):379-386. PubMed ID: 31419095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
    Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
    Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
    Ghorashian S; Kramer AM; Onuoha S; Wright G; Bartram J; Richardson R; Albon SJ; Casanovas-Company J; Castro F; Popova B; Villanueva K; Yeung J; Vetharoy W; Guvenel A; Wawrzyniecka PA; Mekkaoui L; Cheung GW; Pinner D; Chu J; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Inglott S; Gilmour KC; Ahsan G; Ferrari M; Manzoor S; Champion K; Brooks T; Lopes A; Hackshaw A; Farzaneh F; Chiesa R; Rao K; Bonney D; Samarasinghe S; Goulden N; Vora A; Veys P; Hough R; Wynn R; Pule MA; Amrolia PJ
    Nat Med; 2019 Sep; 25(9):1408-1414. PubMed ID: 31477906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

  • 54. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Comeaux EQ; Mullighan CG
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28003275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
    Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
    Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Yin and Yang-Like Clinical Implications of the
    González-Gil C; Ribera J; Ribera JM; Genescà E
    Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33435487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.
    Kaczmarska A; Śliwa P; Zawitkowska J; Lejman M
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IKZF1 rs4132601 and rs11978267 Gene Polymorphisms and Acute Lymphoblastic Leukemia: Relation to Disease Susceptibility and Outcome.
    Mosaad YM; El-Ziny MA; Darwish A; Al-Harrass M; Abdmabood S; Fawzy IM; Sherif DM; Yakoub MG; Abdeltawab H
    J Pediatr Hematol Oncol; 2020 Oct; 42(7):420-428. PubMed ID: 32769565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.